Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Control of copper status for cancer therapy.

Goodman VL, Brewer GJ, Merajver SD.

Curr Cancer Drug Targets. 2005 Nov;5(7):543-9. Review.

PMID:
16305350
2.

Copper deficiency as an anti-cancer strategy.

Goodman VL, Brewer GJ, Merajver SD.

Endocr Relat Cancer. 2004 Jun;11(2):255-63. Review.

3.

Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.

Brewer GJ, Merajver SD.

Integr Cancer Ther. 2002 Dec;1(4):327-37. Review.

PMID:
14664727
4.

Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.

Brewer GJ.

Curr Cancer Drug Targets. 2005 May;5(3):195-202. Review.

PMID:
15892619
5.

Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.

Khan G, Merajver S.

Expert Opin Investig Drugs. 2009 Apr;18(4):541-8. doi: 10.1517/13543780902845622 . Review.

PMID:
19335282
6.

Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.

Brewer GJ.

Exp Biol Med (Maywood). 2001 Jul;226(7):665-73. Review.

PMID:
11444102
7.

Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.

Brewer GJ.

J Cell Mol Med. 2003 Jan-Mar;7(1):11-20. Review. Erratum in: J Cell Mol Med. 2003 Apr-Jun;7(2):1 p proceeding table of contents.

8.

Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.

Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD.

Clin Cancer Res. 2003 May;9(5):1666-72.

9.

Cutting copper curbs angiogenesis, studies show.

Vanchieri C.

J Natl Cancer Inst. 2000 Aug 2;92(15):1202-3. No abstract available.

PMID:
10922401
10.

Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.

Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD.

Clin Cancer Res. 2000 Jan;6(1):1-10.

11.

The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.

Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD.

Laryngoscope. 2001 Apr;111(4 Pt 1):696-701.

PMID:
11359142
12.

Copper chelation as an antiangiogenic therapy.

Lowndes SA, Harris AL.

Oncol Res. 2004;14(11-12):529-39. Review.

PMID:
15666995
13.

Anticopper therapy against cancer and diseases of inflammation and fibrosis.

Brewer GJ.

Drug Discov Today. 2005 Aug 15;10(16):1103-9. Review.

PMID:
16182195
14.

Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma.

Khan MK, Mamou F, Schipper MJ, May KS, Kwitny A, Warnat A, Bolton B, Nair BM, Kariapper MS, Miller M, Brewer G, Normolle D, Merajver SD, Teknos TN.

Arch Otolaryngol Head Neck Surg. 2006 Mar;132(3):333-8.

PMID:
16549755
15.

Antiangiogenic therapy through copper chelation.

Sproull M, Brechbiel M, Camphausen K.

Expert Opin Ther Targets. 2003 Jun;7(3):405-9. Review.

PMID:
12783576
16.

The use of copper-lowering therapy with tetrathiomolybdate in medicine.

Brewer GJ.

Expert Opin Investig Drugs. 2009 Jan;18(1):89-97. doi: 10.1517/13543780802621859 . Review.

PMID:
19053885
17.
18.

Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.

Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH.

J Lab Clin Med. 2003 Mar;141(3):210-6.

PMID:
12624602
19.

A requirement for copper in angiogenesis.

Harris ED.

Nutr Rev. 2004 Feb;62(2):60-4. Review.

PMID:
15080367
20.

Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.

Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G, Smith DC.

Oncology. 2006;71(3-4):168-75. Epub 2007 Jul 18.

PMID:
17641535

Supplemental Content

Support Center